Roshawn Blunt

Venture Partner

Roshawn joined Omega Funds in 2023. She is the president of Corsaire Corporation, a pharmaceutical commercialization organization, and a Board member of Reneo Pharmaceuticals (NASDAQ: RPHM) and Omega portfolio company Kronos Bio (NASDAQ: KRON).

Roshawn founded and was the managing director of 1798, LLC, a national health care consulting firm. Prior to starting 1798, she was Vice President of Strategy, Planning, and Communication at Long Beach Memorial Center and Miller Children's Hospital. Roshawn was the first Global Director of Health Economics and Reimbursement for Biosense Webster, Inc., a Johnson & Johnson company. She also held a variety of strategic reimbursement and commercialization positions at Amgen, Inc. Roshawn began her pharmaceutical career at The Boston Consulting Group, working primarily in the health care industry.

Roshawn graduated from Princeton University, where she earned her A.B. from the Princeton School of Public and International Affairs, and she holds an MBA from Kellogg School of Management at Northwestern University.